Literature DB >> 10570970

The promoter region of human prepro-nociceptin gene and its regulation by cyclic AMP and steroid hormones.

G X Xie1, E Ito, K Maruyama, Y Suzuki, S Sugano, M Sharma, C Pietruck, P P Palmer.   

Abstract

The promoter and upstream regulatory region of the human prepro-nociceptin gene has been cloned from adaptor-ligated genomic DNA libraries by polymerase chain reaction. This 1.7 kb region contains several potential binding sites for transcription factors, among which are binding sites for TF-IID, cyclic AMP response element binding protein, glucocorticoid receptor and estrogen receptor. Multiple start points for the transcription of prepro-nociceptin are identified by an 'oligoribonucleotide-capping' method, but the major one is located at -558(G). Promoter activity assays using luciferase reporter gene constructions with the 1.7 kb fragment and a series of deletion mutations demonstrate that the core promoter is located in the region from -639 to -521 (a region surrounding the major transcription start point -558). A TATA-box motif displays weak promoter activity. An increase of cellular cyclic AMP levels by forskolin treatment up-regulates prepro-nociceptin transcription. Estrogen also up-regulates gene transcription whereas glucocorticoid down-regulates transcription, each through their corresponding receptor response elements. These regulatory effects can be blocked either by mutations of the potential cyclic AMP- or estrogen receptor response elements or by the application of antagonists for glucocorticoid and estrogen receptors. These findings provide a molecular basis for the regulatory mechanisms of human prepro-nociceptin gene expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570970     DOI: 10.1016/s0378-1119(99)00350-9

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma.

Authors:  Aldo Spadaro; Antonino Ajello; Carmelo Luigiano; Carmela Morace; Maria Letizia Resta; Grazia Berlinghieri; Salvatore Campo; Claudio Scisca; Angela Alibrandi; Graziella D'Arrigo; Nunziata Alessi; Oscar Ferrau; Maria Antonietta Freni
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

2.  Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma.

Authors:  Ferenc Szalay; Monika B Hantos; Andrea Horvath; Peter L Lakatos; Aniko Folhoffer; Kinga Dunkel; Dalma Hegedus; Kornelia Tekes
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 3.  Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists.

Authors:  Jong Yung Park; Suji Chae; Chang Seop Kim; Yoon Jae Kim; Hyun Joo Yi; Eunjoo Han; Youngshin Joo; Surim Hong; Jae Won Yun; Hyojung Kim; Kyung Ho Shin
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

4.  Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice.

Authors:  Victor A D Holanda; Matheus C Oliveira; Edilson D Da Silva Junior; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Neurobiol Stress       Date:  2020-10-05

5.  Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats.

Authors:  G Delaney; K L Dawe; R Hogan; T Hunjan; J Roper; G Hazell; S J Lolait; A J Fulford
Journal:  J Neuroendocrinol       Date:  2012-12       Impact factor: 3.627

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.